EUCTR2006-003169-15-SE进行中（未招募）不适用
A Phase 2 study of temozolomide (SCH 52365) in Subjects with Advanced Aerodigestive Tract Cancers Selected for Methylation of O6-Methyl-guanine-DNA Methyltransferase (MGMT) Promoter
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 160
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •M1. Subject must have one of the following histologically or cytologically confirmed tumor types: a. CRC: metastatic disease. b. NSCLC: locally advanced, inoperable, or metastatic disease. Eligible histologies include (but are not restricted to) squamous cell, adenocarcinoma, adenosquamous carcinoma, and large cell carcinoma. c. H & N cancer: recurrent or metastatic disease, including squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx or larynx. d. Esophageal cancer: recurrent or metastatic disease, including (but not restricted to) squamous cell carcinoma and adenocarcioma and also including cancers at the gastroesophageal junction.
- •2. Subjects must have a tumor sample, when available from initial diagnosis or later, and a serum sample taken during the screening period. The available tumor samples can be from biopsy or surgical resection of primary or metastatic lesions. If a subject has no prior surgical resection or biopsy of the tumor, or the available tumor sample is insufficient for screening, and a new biopsy for screening is not clinically indicated, the subject may be screened based on the serum sample alone.
- •3. Subjects must demonstrate methylated MGMT promoter in the most recent tumor tissure sample or in the serum sample.
- •4. Subjects must have relapsed or recurrent disease with no other potentially curative treatment option available in the opinion of the investigator.
- •5. Subjects must meet the requirement listed below regarding their prior chemotherapy, biological therapy, immunotherapy, or targeted therapy for advanced/metastatic disease. In addition to the prior therapy limits below, subjects may also have received adjuvant or neoadjuvant therapy. a. CRC: no more than 3 prior regimens. b. NSCLC: no more than 3 prior regimens. c. H & N cancer: no more than 2 prior regimens. d. Esophageal cancer: no more than 2 prior regimens.
- •6. Subjects must have resolution of all clinically significant toxic effects (excluding alopecia, acne, skin rash) of any prior surgery, radiotherapy, immunotherapy, targeted therapy or chemotherapy to Grade7. Subjects must have at least one measureable lesion, as defined by Response Evaluation Criteria in Solid Tumors (RESIST). If the subject has received radiation therapy, this measurable lesion must be outside the area of prior radiation or has demonstrated clear progression following completion of radiation therapy.
- •8. Subjects must have an Eastern Coorperative Oncology group (ECOG) performance status of 0, 1 or 2.
- •9. Subjects must have adequate hematologic, renal, and liver function, as demonstrated by laboratory values performed within 14 days, inclusive, prior to administration of study drug: a. Absolute neutrophil count >/= 1, 500/mm3 b. Platelet count >/=100,000/mm3 c. Hemoglobin >/=9g/dl d. Blood urea nitrogen (BUN)/urea and serum creatinine 10. Subjects must be able to take the study medication capsules orally, or through a feeding tube without the capsules being opened.
- •Are the trial subjects und
排除标准
- •Subjects will be excluded from entry if any of the criteria are met:
- •1. Subjects who have received treatment for a second malignancy within 1 year before screening, and are considered to be at risk of relapse within 1 year after screening.
- •2. Subjects with unstable or progressing CNS metastasis. Subjects with known CNS metastasis may be included if a) the subject is asymptomatic, b)there is no requirement for steroids or antiseizure medications, or the required doses are stable, and c) there is no associated midline shift or (in the opinion of the investigator) significant edema.
- •3. Subjects with clinically relevant cardiovascular, hepatic, neurologic, endocrine, or other major systemic disease that would make implementation of the protocol difficult.
- •4. Subjects who received prior temozolomide or dacarbazine treatment.
- •5. Women who are breast-feeding, pregnant, or intend to become pregnant.
- •6. Subjects with any clinically significant condition or situation, other than the condition being studied that, in the opinion of the investigator, would interfere with the study evaluations or optimal participation in the study.
- •7. Subjects who have used any investigational drugs within 30 days of start of study treatment 8. Subjects who are participating in any other therapeutic clinical study. Subjects who are in the follow-up phase and have been at least 30 days off the study treatments in other studies may be allowed.
研究者
相似试验
进行中（未招募）
1 期
A Phase 2 study of temozolomide (SCH 52365) in Subjects with Advanced Aerodigestive Tract Cancers Selected for Methylation of O6-Methyl-guanine-DNA Methyltransferase (MGMT) PromoterAdvanced Aerodigestive Tract Cancers (Colorectal Cancer (CRC), Non Small Cell Lung Cancer (NSCLC), Head and Neck (H&N), Esophageal CancerMedDRA version: 8.1 Level: LLT Classification code 10028980 Term: NeoplasmEUCTR2006-003169-15-CZSchering Plough Research Institute160
进行中（未招募）
1 期
A Phase 2 study of temozolomide (SCH 52365) in Subjects with Advanced Aerodigestive Tract Cancers Selected for Methylation of O6-Methyl-guanine-DNA Methyltransferase (MGMT) PromoterAdvanced Aerodigestive Tract Cancers (Colorectal Cancer (CRC), Non Small Cell Lung Cancer (NSCLC), Head and Neck (H&N), Esophageal CancerMedDRA version: 8.1 Level: LLT Classification code 10028980 Term: NeoplasmEUCTR2006-003169-15-GBSchering Plough Research Institute160
进行中（未招募）
不适用
A Phase 2 study of temozolomide (SCH 52365) in Subjects with Advanced Aerodigestive Tract Cancers Selected for Methylation of O6-Methyl-guanine-DNA Methyltransferase (MGMT) PromoterAdvanced Aerodigestive Tract Cancers (Colorectal Cancer (CRC), Non Small Cell Lung Cancer (NSCLC), Head and Neck (H&N), Esophageal CancerMedDRA version: 8.1Level: LLTClassification code 10028980Term: NeoplasmEUCTR2006-003169-15-NLSchering Plough Research Institute160
进行中（未招募）
不适用
A Phase 2 study of temozolomide (SCH 52365) in Subjects with Advanced Aerodigestive Tract Cancers Selected for Methylation of O6-Methyl-guanine-DNA Methyltransferase (MGMT) PromoterAdvanced Aerodigestive Tract Cancers (Colorectal Cancer (CRC), Non Small Cell Lung Cancer (NSCLC), Head and Neck (H&N), Esophageal CancerMedDRA version: 8.1Level: LLTClassification code 10028980Term: NeoplasmEUCTR2006-003169-15-PTSchering Plough Research Institute160
进行中（未招募）
1 期
A Phase 2 Study of Temozolomide (SCH 52365) in Subjects With Advanced Aerodigestive Tract Cancers Selected for Methylation of O6-Methyl-Guanine-DNA Methyltransferase (MGMT) Promoter. - P04273Advanced Aerodigestive Tract Cancers (Colorectal Cancer (CRC), Non Small Cell Lung Cancer (NSCLC), Head & Neck (H & N), Esophageal Cancer).MedDRA version: 9.1 Level: LLT Classification code 10028980 Term: NeoplasmEUCTR2006-003169-15-ITSCHERING-PLOUGH160